BioCentury
ARTICLE | Top Story

Intercept surges on lipid data

August 13, 2014 12:24 AM UTC

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) jumped $39.34 (17%) to $276.52 on Tuesday after reporting additional data late Monday from the Phase II FLINT trial of obeticholic acid in non-alcoholic steatohepatitis (NASH) patients. The results are the first window into the magnitude of changes in serum lipid levels in OCA patients vs. placebo. Intercept said the changes "decreased in magnitude while on treatment and effectively returned to baseline during the 24-week post-treatment period."

Specifically, 25 mg of OCA at 72 weeks significantly increased mean total cholesterol and LDL-C levels vs. placebo and significantly reduced HDL-C levels vs. placebo. OCA non-significantly reduced mean triglyceride levels from baseline to week 72 vs. placebo. After the 24-week post-treatment period, there were no significant differences between treatment groups in total cholesterol, LDL-C, HDL-C or triglyceride levels. ...